TrialFrontiers in immunology2022

Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study.

Dailong Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.